Binds A Cancer Cell Or Component Or Product Thereof (e.g., Cell Surface Antigen, Etc.) Patents (Class 435/344)
-
Publication number: 20030153017Abstract: The invention concerns antibodies capable of identifying the prostrate specific antigen (PSA) in non-complexed and inactive form, and their uses in methods for diagnosing an adenocarcinoma or benign prostatic hyperplasia.Type: ApplicationFiled: February 6, 2003Publication date: August 14, 2003Inventors: Jean-Philippe Charrier, Colette M Jolivet-Reynaud, Sandrine Michel
-
Publication number: 20030152575Abstract: The present invention provides methods and compositions for treating HMFG- and CEA-associated tumors using the anti-idiotype antibody 11D10 in conjunction with anti-idiotype antibody 3H1.Type: ApplicationFiled: February 13, 2003Publication date: August 14, 2003Inventors: Malaya Chatterjee, Kenneth A. Foon
-
Publication number: 20030148511Abstract: The present invention provides methods for enhancing host immunity to a virus and/or a cancer and methods for enhancing the cytotoxic T-cell (CTL) mediated immune responses by providing granzyme B inhibitors to a subject. One objective of the invention is to induce long-term protective immunity to a subject in need thereof This is accomplished by providing granzyme inhibitors to the subject which increase the number of memory-CTLs and thereby prevent or alleviate viral infections and/or treat. Providing granzyme inhibitors is also effective in the prevention of cancers. Some examples of granzyme inhibitors contemplated within the present invention include the endogenous serpins such as SPI6 and PI9, other suicide substrates of granzyme B, granzyme B antibodies, etc. Also provided are methods for expression of nucleic acids encoding granzyme inhibitors in cytotoxic T-lymphocytes (CTLs).Type: ApplicationFiled: November 14, 2001Publication date: August 7, 2003Inventors: Philip G. Ashton-Rickardt, Joseph T. Opferman
-
Publication number: 20030147894Abstract: It is the objective and purpose of the present invention to provide a monoclonal antibody having the property of causing apoptosis on myeloid cells.Type: ApplicationFiled: March 3, 2003Publication date: August 7, 2003Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventor: Naoshi Fukushima
-
Publication number: 20030138428Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: ApplicationFiled: September 6, 2001Publication date: July 24, 2003Inventors: Fernando J.R. do Couto, Roberto L. Ceriani, Jerry A. Peterson, Eduardo A. Padlan
-
Publication number: 20030133939Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.Type: ApplicationFiled: January 17, 2002Publication date: July 17, 2003Applicant: Genecraft, Inc.Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
-
Publication number: 20030124129Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: October 10, 2002Publication date: July 3, 2003Inventor: Jonathan Daniel Oliner
-
Publication number: 20030124057Abstract: The present invention relates to an antibody or antibody fragment that binds to 1,4,7,10-tetrazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA),which is bound to an alkyl-amino group through one of its pendant carb.oxyl groups.Type: ApplicationFiled: November 27, 2002Publication date: July 3, 2003Applicant: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, Serengulam V. Govindan, Michelle Losman, Zhengxing Qu
-
Publication number: 20030113333Abstract: This invention relates to a kit containing a multivalent, multi-specific binding protein and a carrier molecule. The binding protein has two or more binding sites where at least one binding site binds with a hapten moiety and at least one site binds with a target antigen. The carrier molecule contains a linking molecule that bears a diagnostic agent and/or a therapeutic agent and two or more haptens. The present invention further relates to bispecific diabodies that bind with hapten moieties and target antigens and to recombinant vectors useful for the expression of these-functional diabodies in a microbial host.Type: ApplicationFiled: October 15, 2002Publication date: June 19, 2003Applicant: Immunomedics, Inc.Inventors: Edmund Rossi, Chien-Hsing Ken Chang
-
Publication number: 20030096285Abstract: The present invention is directed to a method for identifying anti-tumor targets by examining lipid rafts. It provides for a method for identifying anti-tumor targets by lipid raft proteomics and a method for identifying anti-tumor agents by lipid rafts immunization. It also provides for hybridomas produced by the method of identifying anti-tumor agents by lipid raft immunization, and antibodies produced by the hybridomas. It also provides for the anti-tumor targets or agents identified by the methods in the present invention.Type: ApplicationFiled: October 10, 2002Publication date: May 22, 2003Inventors: J. Yun Tso, Jennifer McPhate Green
-
Publication number: 20030092125Abstract: The present invention provides a method of biasing the immune response of a mammal toward a desired epitope of a chosen antigen, particularly a functionally-relevant epitope. In preferred embodiments, the epitope-biasing method leads to fully-human antibodies of defined specificity with affinities of 10 nM to 50 pM. The invention further provides antibody libraries biased to tissues and to cell types, for use in generating epitope expression profiles useful for characterizing unknown genes. When all aspects of the present invention are combined, they result in an integrated system for defining critical epitopes on newly discovered gene products and rapidly devloping therapeutic grade antibodies to those critical epitopes.Type: ApplicationFiled: October 23, 2002Publication date: May 15, 2003Applicant: Abgenix, Inc.Inventors: Claude Geoffrey Davis, Aya Jakobovits
-
Patent number: 6541253Abstract: The present invention is directed to monoclonal antibodies capable of specifically binding to and recognizing an antigenic determinant (epitope) of the protein kaposin or a derivative thereof, hybridoma cell lines producing said monoclonal antibodies, diagnostic systems for the detection of the presence of a kaposin protein or a derivative thereof as well as antibodies directed against the kaposin protein or a derivative thereof, methods for detection of the expression of kaposin protein or a derivative thereof in a biological sample, methods for the detection of antibodies directed against kaposin protein or a derivative thereof, uses of the monoclonal antibodies provided according to the invention and uses of the kaposin protein or a derivative thereof, each in diagnostics and therapy.Type: GrantFiled: May 16, 2001Date of Patent: April 1, 2003Assignee: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbHInventors: Juergen Haas, Elisabeth Kremmer, Stefanie Kliche
-
Publication number: 20030045485Abstract: The invention is directed to a methods of reducing the viability of a proliferating mammalian cells such as cancer cells. In one method cells deficient in p53 activity and in p53 suppressor activity of one or more p53-interacting regulatory proteins cell viability is reduced by increasing the level or activity of p53 in the cell. In another method viability of cells exhibiting p53 activity and p53 suppressor activity of one or more p53-interacting regulatory proteins is reduced by reducing the suppressor activity of the one or more p53-interacting regulatory proteins. Further, cell viability is reduced in cells deficient in p53 activity and exhibiting p53 suppressor activity of one or more p53-interacting regulatory proteins by a method that includes: (a) increasing the level or activity of p53 in the cell, and (b) reducing the suppressor activity of the one or more p53-interacting regulatory proteins.Type: ApplicationFiled: June 5, 1995Publication date: March 6, 2003Inventors: MICHAEL F. CLARKE, JAMES J. RYAN, GABRIEL NUNEZ
-
Patent number: 6482614Abstract: The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results in a decrease of an individual's immune response to his or her own cells. The present invention also relates to compositions comprising a stress protein joined to another component, such as a fusion protein in which a stress protein is fused to an antigen. Further, the present invention relates to a method of generating antibodies to a substance using a conjugate comprised of a stress protein joined to the substance.Type: GrantFiled: December 21, 1999Date of Patent: November 19, 2002Assignee: Whitehead Institute for Biomedical ResearchInventor: Richard A. Young
-
Patent number: 6479241Abstract: A high-throughput method for screening compounds for anticancer activity involves cultivating cells capable of expressing cancer genes in cell culture in microtiter plate wells in the presence of test compounds and detecting the level of gene expression by a quantitative nucleic acid amplification.Type: GrantFiled: September 8, 2000Date of Patent: November 12, 2002Assignee: Southern Research InstituteInventor: Alex Aller
-
Publication number: 20020127714Abstract: Disclosed are methods for the treatment of proliferative disorders using compounds and/or environmental conditions which result in a difference in sensitivity of targeted and non-targeted cells. Certain of the methods involve the identification and use of allele-specific inhibitors of conditionally essential genes.Type: ApplicationFiled: February 14, 2001Publication date: September 12, 2002Applicant: Variagenics, Inc., a Delaware corporationInventors: David E. Housman, Fred D. Ledley, Vincent P. Stanton
-
Patent number: 6447776Abstract: The present invention describes monoclonal antibodies which are useful for the specific detection of diffuse gastric carcinoma. Further embodiments describe therapeutic and diagnostic means for the detection and for the therapy of diffuse gastric carcinomas.Type: GrantFiled: July 23, 1997Date of Patent: September 10, 2002Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Heinz Höfler, Karl-Friedrich Becker, Elisabeth Kremmer, Manfred Eulitz, Christoph Schuhmacher
-
Patent number: 6440733Abstract: A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing said monoclonal antibody, pharmaceutical agents comprising said monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of said monoclonal antibody and another conjugating molecule.Type: GrantFiled: August 17, 1998Date of Patent: August 27, 2002Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tadanori Mayumi, Shinsaku Nakagawa, Yasuo Tsutsumi, Iwao Ohizumi
-
Publication number: 20020098581Abstract: Carcinoma associated antigen (SK1) and monoclonal antibodies and methods for detecting and ameliorating malignant disease. The monoclonal antibodies are specifically reactive with epitopes present on SK1.Type: ApplicationFiled: December 20, 2001Publication date: July 25, 2002Inventors: Mark C. Glassy, Helena R. Chang, Keiji Koda
-
Publication number: 20020098190Abstract: The present invention provides methods and compositions for treating HMFG- and CEA-associated tumors using the anti-idiotype antibody 11D10 in conjunction with anti-idiotype antibody 3H1.Type: ApplicationFiled: May 17, 2001Publication date: July 25, 2002Inventors: Malaya Chatterjee, Kenneth A. Foon
-
Publication number: 20020081305Abstract: A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing said monoclonal antibody, pharmaceutical agents comprising said monoclonal antibody, as well as pharmaceutical or diagnostic agents comprising a conjugate of said monoclonal antibody and another conjugating molecule.Type: ApplicationFiled: November 8, 2001Publication date: June 27, 2002Inventors: Tadanori Mayumi, Shinsaku Nakagawa, Yasuo Tsutsumi, Iwao Ohizumi
-
Patent number: 6410319Abstract: Genetically engineered, CD20-specific redirected T cells expressing a cell surface protein-having an extracellular domain comprising a receptor which is specific for CD20, an intracellular signaling domain, and a transmembrane domain. Use of such cells for cellular immunotherapy of CD20+ malignancies and for abrogating any untoward B cell function. In one embodiment, the cell surface protein is a single chain FvFc:&zgr; receptor where Fv designates the VH and VL chains of a single chain monoclonal antibody to CD20 linked by peptide, Fc represents a hinge-CH2-CH3 region of a human IgG1, and &zgr; represents the intracellular signaling domain of the zeta chain of human CD3. A method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.Type: GrantFiled: October 20, 1999Date of Patent: June 25, 2002Assignee: City of HopeInventors: Andrew Raubitschek, Anna Wu, Michael C. Jensen
-
Publication number: 20020058291Abstract: Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.Type: ApplicationFiled: February 23, 2001Publication date: May 16, 2002Inventors: Stephen D. Mikolajczyk, Harry G. Rittenhouse, Abhay Kumar, Mohammad S. Saedi, Robert L. Wolfert
-
Patent number: 6376654Abstract: The present invention is directed to cell surface antigens found on myeloma cells and on ovarian cancer cells, and monoclonal antibodies and binding fragments thereto capable of being used for therapeutic, diagnostic, and cell purification purposes.Type: GrantFiled: August 13, 1999Date of Patent: April 23, 2002Assignee: Molecular Discoveries, LLCInventor: Cohava Gelber
-
Publication number: 20020015704Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: ApplicationFiled: August 13, 2001Publication date: February 7, 2002Applicant: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Publication number: 20020009724Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cervical cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of cervical cancer.Type: ApplicationFiled: December 8, 2000Publication date: January 24, 2002Inventors: Robert Schlegel, James D. Deeds, Allison Berger, Xumei Zhao
-
Patent number: 6322787Abstract: According to the invention, there is provided a human or animal cell expressing an antibody directed against a surface antigen on an antigen-presenting cell (APC) and lacking parental tumor-derived immunoglobulin.Type: GrantFiled: August 5, 1999Date of Patent: November 27, 2001Assignee: GSF Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Ralph Mocikat, Horst Lindhofer
-
Patent number: 6306575Abstract: The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells.Type: GrantFiled: December 1, 1995Date of Patent: October 23, 2001Assignee: StemCell Technologies, Inc.Inventors: Terry Thomas, Peter Lansdorp
-
Patent number: 6306615Abstract: This invention relates to monoclonal antibodies that recognize modified &bgr;-tubulin isotypes, methods of using such antibodies to detect modified &bgr;-tubulin isotypes, methods of using such antibodies to monitor &bgr;-tubulin modifying agents administered to a patient, methods of using such antibodies to isolate modified &bgr;-tubulin, and methods of detecting the anti-modified &bgr;-tubulin antibodies.Type: GrantFiled: August 19, 1999Date of Patent: October 23, 2001Assignee: Tularik Inc.Inventors: Holger Beckmann, Edit Santha
-
Patent number: 6294172Abstract: Monoclonal antibodies with specificity for membrane-associated antigens and methods of using them in detection of tumor-associated antigens arc described.Type: GrantFiled: February 1, 1995Date of Patent: September 25, 2001Assignee: Dade Behring Marburg GmbHInventors: Klaus Bosslet, Roland Kurrle, Hans Harald Sedlacek, Ernst-Jurgen Kanzy, Takako Katoh, Hans Ulrich Schorlemmer, Gerhard Luben
-
Patent number: 6258939Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: December 2, 1998Date of Patent: July 10, 2001Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte
-
Patent number: 6245898Abstract: This invention provides tumor metastasis-inhibiting monoclonal antibodies, mAb 41-2, mAb 50-6 and mAb 1A-5. The antigen recognized by mAb 50-6 and mAb 1A-5 has been identified as the PETA-3 antigen. The antigen recognized by mAb 41-2 has been identified as a novel tumor metastasis-associated antigen. Compositions and methods are provided that are useful for treating and diagnosing metastatic tumors.Type: GrantFiled: June 15, 1999Date of Patent: June 12, 2001Assignee: The Research Foundation of State University of New YorkInventors: Jacqueline E. Testa, James P. Quigley, Marco Seandel
-
Patent number: 6201107Abstract: The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.Type: GrantFiled: June 6, 1995Date of Patent: March 13, 2001Assignees: HSC Research Development Corporation, The Board of Regents, Acting for and on Behalf of the University of MichiganInventors: Tsui Lap-Chee, John R. Riordan, Francis S. Collins, Johanna M. Rommens, Michael C. Iannuzzi, Bat-Sheva Kerem, Mitchell L. Drumm, Manuel Buchwald
-
Patent number: 6200763Abstract: A gene, mcl-1, of the bcl-2 family is disclosed along with its nucleotide and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of utilizing the mcl-1 nucleotide and polypeptide sequences.Type: GrantFiled: August 20, 1999Date of Patent: March 13, 2001Assignee: Dartmouth CollegeInventor: Ruth W. Craig
-
Patent number: 6174726Abstract: The invention is directed to a method for the preparation of a conditionally immortalized immortalization-helper cell (fuseme), the fusemes generated by said method, hybridoma cells prepared using said fusemes as well as a method for immortalization of mammalian cells using said fuseme cells. Further, the invention relates to the generation of T cells directed agaist tumor cells using a fuseme cell.Type: GrantFiled: April 1, 1999Date of Patent: January 16, 2001Assignee: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbHInventors: Martin Staege, Georg Bornkamm, Bettina Kempkes
-
Patent number: 6162902Abstract: The present invention provides reagents and assays for the quantification of hBNP in biological fluid samples such as plasma or serum. Antibodies are provided which are monospecific to epitopes comprising the amino acid sequences 5-13, 1-10 and 15-25 of hBNP. These antibodies, and peptide fragments containing these sequences, can be employed in the assays of the invention, which may be carried out in a sandwich format or a competition format.Type: GrantFiled: October 1, 1997Date of Patent: December 19, 2000Assignee: Scios Inc.Inventors: Ronald P. Mischak, Garrett A. Lim, Jan Marian Scardina
-
Patent number: 6159751Abstract: This invention provides a method for preparing a hybridoma cell line which produces a monoclonal antibody which specifically recognizes and binds to a tumor associated antigen which comprises: (a) cotransfecting a CREF-Trans 6 cell line with DNA isolated from a neoplastic, human cell and a plasmid which encodes a selectable or identifiable trait; (b) selecting transfected cells which express the selectable or identifiable trait; (c) recovering the cells so selected in step (b); (d) injecting the cells so recovered in step (c) into a suitable marine host; (e) maintaining the resulting first murine host for a period of time effective to induce the cells injected in step (d) to form a tumor in the murine host; (f) isolating the tumor formed in step (e); (g) obtaining tumor cells from the isolated tumor in step (f); (h) coating the tumor cells obtained in step (9) with an antiserum generated against the CREF Trans-6 cell line (i) injecting the antiserum-coated cells from step (h) into a plurality of suitable secoType: GrantFiled: June 5, 1995Date of Patent: December 12, 2000Assignee: The Trustees of Columbia University in the City of New YorkInventor: Paul B. Fisher
-
Patent number: 6156307Abstract: The present invention refers to immortalized dendritic cells, to a process for their production from primary cultures and to their use for the activation, in vivo or in vitro, of T lymphocytes in antigen specific way.Type: GrantFiled: January 2, 1998Date of Patent: December 5, 2000Assignee: Biotop s.a.s. di Rita CassarinInventor: Francesca Granucci
-
Patent number: 6150116Abstract: The invention provides a polynucleotide in substantially isolated form which includes a contiguous sequence of nucleotides which is capable of selectively hybridizing to SEQ ID NO: 1 or the complement of SEQ ID NO: 1, and a polypeptide in substantially isolated form which includes: (a) the protein in SEQ ID NO: 2; or (b) an allelic variant or species homologue thereof; or (c) a protein at least 70% homologous to (a); or (d) a fragment of any one of (a) to (c) capable of forming a complex with the E2 F-1 protein or related family member; or (e) a fragment of any one of (a) to (c) of at least 15 amino acids.Type: GrantFiled: May 14, 1998Date of Patent: November 21, 2000Assignee: Medical Research CouncilInventor: Nicholas Barrie La Thangue
-
Patent number: 6143873Abstract: This invention relates generally to the field of immunology, in particular that of antibodies and antibody productions. More specifically, this invention relates to bispecific antibodies, the hybrid hybridomas which produce them, the parent hybridomas, the production and selection of the hybridomas and hybrid hybridomas, and the purification of the bispecific antibodies. Specific examples relate to bispecific monoclonal antibodies which recognize both the human multi-drug resistance antigen, P-glycoprotein and human Fc.gamma. receptor III (hFc.gamma.RIII. These bispecific antibodies are useful in killing cancer cells.Type: GrantFiled: June 22, 1999Date of Patent: November 7, 2000Assignee: Chiron CorporationInventors: David Ring, Tian-Xiang Shi
-
Patent number: 6139869Abstract: A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anti-cancer agent or toxin is also provided.Type: GrantFiled: May 25, 1995Date of Patent: October 31, 2000Assignee: Mitsubishi Kasei CorporationInventors: Saiko Hosokawa, Toshiaki Tagawa, Yoko Hirakawa, Norihiko Ito, Kazuhiro Nagaike
-
Patent number: 6107090Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.Type: GrantFiled: April 9, 1997Date of Patent: August 22, 2000Assignee: Cornell Research Foundation, Inc.Inventor: Neil H. Bander
-
Patent number: 6106833Abstract: This invention relates generally to the field of immunology, in particular that of antibodies and antibody productions. More specifically, this invention relates to bispecific antibodies, the hybrid hybridomas which produce them, the parent hybridomas, the production and selection of the hybridomas and hybrid hybridomas, and the purification of the bispecific antibodies. Specific examples relate to bispecific monoclonal antibodies which recognize both the human multi-drug resistance antigen, P-glycoprotein and human Fc.gamma. receptor III (hFc.gamma.RIII). These bispecific antibodies are useful in killing cancer cells.Type: GrantFiled: November 12, 1997Date of Patent: August 22, 2000Assignee: Chiron CorporationInventors: David Ring, Tian-Xiang Shi
-
Patent number: 6090924Abstract: CLNH5-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.Type: GrantFiled: June 7, 1995Date of Patent: July 18, 2000Assignee: The Regents of the University of CaliforniaInventors: Harold H. Handley, Mark C. Glassy, Hideaki Hagiwara, Yoshihide Hagiwara
-
Patent number: 6075127Abstract: The invention provides for a method for the modification of (poly)peptides for facilitating purification thereof, which modification method comprises the insertion of at least one specifically cleavable amino acid at the end of the (poly)peptide chain during synthesis thereof and protecting the same amino acid(s) within the (poly)peptide, if present, against cleavage, in order to allow for specific cleavage precisely at the specifically cleavable amino acid(s). The invention further relates to a process for the preparation of purified (poly)peptides using the modification method.Type: GrantFiled: May 26, 1999Date of Patent: June 13, 2000Assignee: RMF Dictagene SAInventors: Mario Roggero, Giampietro Corradin, Christophe Reymond, Nicolas Fasel
-
Patent number: 6063586Abstract: A cancer prognostic having particular utility in the prognosis of head and neck squamous cell cancer, in which the expression levels of either or both of Transforming Growth Factor Alpha (TGF-.alpha.) or Epidermal Growth Factor Receptor (EGFR) are assayed directly from a sample of tumor tissue. The expression level once quantitated is normalized as to standard, and the standardized expression level is compared to the prognostic threshold of about 83% of standard for TGF-.alpha. or of about 23% of standard for EGFR, or the corresponding upper threshold of the "low" tertile regardless of how calculated. Virtually all if not all patients demonstrating this low expression level survive at least five years after initial diagnosis, assuming completion of treatment with standard surgical tumor excision and radiation protocols for squamous cell head and neck cancer. Whether an individual patient's expression levels of TGF-.alpha.Type: GrantFiled: February 4, 1998Date of Patent: May 16, 2000Assignee: Eye & Ear FoundationInventor: Jennifer Rubin Grandis
-
Patent number: 6060255Abstract: A type IV collagen high molecular form having a higher molecular weight than the 7S domain of type IV collagen and including the 7S domain in its structure, is obtained from the supernatant being recovered from a collagen solution digested by pepsin in the following steps;1) salt precipitating with sodium chloride at a concentration no higher than 1.2 M,2) dissolving the precipitates,3) salt precipitating with sodium chloride at a concentration no higher than previous concentration. By reacting a sample with an antibody which reacts with this form, the type IV collagen high molecular form in the sample can be measured to allow diagnosis of the degree of liver fibrosis in patients with liver diseases.Type: GrantFiled: October 1, 1998Date of Patent: May 9, 2000Assignees: Tosoh Corporation, Morinaga & Co., Ltd.Inventors: Akitaka Shibuya, Shunji Saitoh, Toshio Takahashi, Naoko Maruo
-
Patent number: 6054297Abstract: Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.Type: GrantFiled: May 9, 1995Date of Patent: April 25, 2000Assignee: Genentech, Inc.Inventors: Paul J. Carter, Leonard G. Presta
-
Patent number: 6051693Abstract: CLNH11-specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.Type: GrantFiled: June 7, 1995Date of Patent: April 18, 2000Assignee: The Regents of the University of CaliforniaInventors: Harold H. Handley, Mark C. Glassy, Hideaki Hagiwara, Yoshihide Hagiwara
-
Patent number: 6051229Abstract: CLNH5 and CLNH11 specific hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.Type: GrantFiled: May 18, 1995Date of Patent: April 18, 2000Assignee: The Regents of the University of CaliforniaInventors: Harold H. Handley, Mark C. Glassy, Hideaki Hagiwara, Yoshihide Hagiwara